Loading asset research
Relmada Therapeutics Inc. Common Stock
RLMDNasdaq · USD · StocksQuote as of · Exchange session not verified$4.53
+11.30%
Today
RLMD
Loading 1D prices…
Market cap
$482.1M
Volume
2.6M
52w high
$8.0052w low
$1.45Company profile
Relmada Therapeutics Inc. Common Stock
Relmada Therapeutics, Inc. operates as a clinical-stage biotechnology company in the United States. The company focuses on the development of NDV-01, a controlled-release intravesical formulation of gemcitabine and docetaxel, which is in Phase 2 clinical trial for patients with aggressive forms of non-muscle invasive bladder cancer; and Sepranolone, a neurosteroid epimer of allopregnanolone, which is Phase 2b-ready for the potential treatment of prader-willi syndrome, tourette syndrome, excessive tremor, and other diseases related to excessive GABAergic activity. The company has an agreement with Asarina Pharma AB and Trigone. Relmada Therapeutics, Inc. was founded in 2004 and is headquartered in Coral Gables, Florida.
Sector
Health Care
Industry
Pharmaceutical Preparations
Exchange
Nasdaq
Display currency
USD
Location
Coral Gables, FL, United States
Employees
17
Fiscal year end
1231
CIK
1553643
Session & valuation
Open$4.60
Previous close$4.07
Day high$4.65
Day low$4.30
30-day avg. volume1.2M
Outstanding shares106.7M
Diluted EPS-$1.45
Latest annual period
P/E (trailing)-3.12
P/E (forward)-8.07
Price / book0.45
Beta—
Dividend yield—
Deterministic peer set
Companies with SEC SIC 2834
Exact regulatory industry matches, ranked by nearest market capitalization.
| Company | Market cap | Revenue | Net margin | Diluted EPS | Today | Consensus |
|---|---|---|---|---|---|---|
| VOGXVogenx Inc Common Stock | $485.9M | $0.00 | — | -$0.2874 | +9.54% | Buy |
| CAPRCapricor Therapeutics Inc. Common Stock | $486.6M | $0.00 | — | -$2.26 | +0.90% | Hold |
| SPRYARS Pharmaceuticals Inc. Common Stock | $473.4M | $84.3M | -203.25% | -$1.74 | -6.52% | Buy |
| PBYIPuma Biotechnology Inc Common Stock | $470.8M | $228.4M | +13.62% | $0.61 | -0.55% | Hold |
| IRDOpus Genetics Inc. Common Stock | $502.5M | $14.2M | -349.33% | -$0.80 | -0.49% | Buy |